Literature DB >> 10780984

Role of kynurenines in the neurotoxic actions of kainic acid.

W M Behan1, T W Stone.   

Abstract

The neurotoxic actions of kainic acid can be partly suppressed by antagonists acting at N-methyl-D-aspartate (NMDA) receptors. The present study examined the possible role of endogenous components of the kynurenine pathway to this phenomenon. Administration of kainate (2 nmols) into the hippocampus of anaesthetized rats produced damage in the CA1 and CA3 regions. The involvement of NMDA receptors was confirmed by the ability of dizocilpine (1 mg kg(-1)) to reduce cell loss in the CA1 region from 92 to 42%. The co-administration of m-nitrobenzoylalanine (20 nmols into the hippocampus), an inhibitor of kynurenine hydroxylase and kynureninase, together with a systemic injection of the compound (100 mg kg(-1), i.p.), afforded some protection against kainate, reducing cell loss from 91 to 48%. Protection was not exerted against damage by quinolinic acid or NMDA, excluding a direct interaction between m-nitrobenzoylalanine and NMDA receptors. The protective effect of m-nitrobenzoylalanine was not prevented by glycine, which would be expected to reverse protection caused by an elevation in the levels of endogenous kynurenic acid, arguing against a major role for increased levels of kynurenic acid. The results indicate that inhibition of the kynurenine pathway offers protection against kainate-induced damage. One possible mechanism for the protection is that an increased production of quinolinic acid in the brain, possibly from glial cells and macrophages activated by the initial kainate insult, normally contributes to the local activation of NMDA receptors and thus to kainate-induced cerebral insults. This generation of endogenous quinolinic acid would be suppressed by m-nitrobenzoylalanine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10780984      PMCID: PMC1572007          DOI: 10.1038/sj.bjp.0703250

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

1.  Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage.

Authors:  D B Clifford; J W Olney; A M Benz; T A Fuller; C F Zorumski
Journal:  Epilepsia       Date:  1990 Jul-Aug       Impact factor: 5.864

2.  Intraventricular kainic acid preferentially destroys hippocampal pyramidal cells.

Authors:  J V Nadler; B W Perry; C W Cotman
Journal:  Nature       Date:  1978-02-16       Impact factor: 49.962

3.  Domoic acid neurotoxicity in cultured cerebellar granule neurons is mediated predominantly by NMDA receptors that are activated as a consequence of excitatory amino acid release.

Authors:  F W Berman; T F Murray
Journal:  J Neurochem       Date:  1997-08       Impact factor: 5.372

4.  Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor.

Authors:  P J Birch; C J Grossman; A G Hayes
Journal:  Eur J Pharmacol       Date:  1988-09-01       Impact factor: 4.432

5.  Activated human microglia produce the excitotoxin quinolinic acid.

Authors:  M G Espey; O N Chernyshev; J F Reinhard; M A Namboodiri; C A Colton
Journal:  Neuroreport       Date:  1997-01-20       Impact factor: 1.837

6.  N-[1-(2-thienyl)cyclohexyl]-piperidine (TCP) does not block kainic acid-induced status epilepticus but reduces secondary hippocampal damage.

Authors:  M Lerner-Natoli; G Rondouin; M Belaidi; M Baldy-Moulinier; J M Kamenka
Journal:  Neurosci Lett       Date:  1991-01-28       Impact factor: 3.046

7.  Microglial and astroglial reactions to ischemic and kainic acid-induced lesions of the adult rat hippocampus.

Authors:  M B Jørgensen; B R Finsen; M B Jensen; B Castellano; N H Diemer; J Zimmer
Journal:  Exp Neurol       Date:  1993-03       Impact factor: 5.330

8.  Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators.

Authors:  D Alberati-Giani; A M Cesura
Journal:  Amino Acids       Date:  1998       Impact factor: 3.520

9.  Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase.

Authors:  R Pellicciari; B Natalini; G Costantino; M R Mahmoud; L Mattoli; B M Sadeghpour; F Moroni; A Chiarugi; R Carpenedo
Journal:  J Med Chem       Date:  1994-03-04       Impact factor: 7.446

10.  Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions.

Authors:  P Russi; M Alesiani; G Lombardi; P Davolio; R Pellicciari; F Moroni
Journal:  J Neurochem       Date:  1992-12       Impact factor: 5.372

View more
  5 in total

1.  Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists.

Authors:  W M H Behan; T W Stone
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 2.  Involvement of kynurenines in Huntington's disease and stroke-induced brain damage.

Authors:  Trevor W Stone; Caroline M Forrest; Nicholas Stoy; L Gail Darlington
Journal:  J Neural Transm (Vienna)       Date:  2011-06-22       Impact factor: 3.575

3.  Adenosine receptor ligands protect against a combination of apoptotic and necrotic cell death in cerebellar granule neurons.

Authors:  Amos A Fatokun; Trevor W Stone; Robert A Smith
Journal:  Exp Brain Res       Date:  2007-11-27       Impact factor: 1.972

Review 4.  Kynurenine Pathway Metabolites as Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Vanessa X Tan; Gilles J Guillemin
Journal:  Front Neurosci       Date:  2019-09-20       Impact factor: 4.677

Review 5.  Tryptophan metabolism: Mechanism-oriented therapy for neurological and psychiatric disorders.

Authors:  Dan Li; Shuang Yu; Yu Long; Ai Shi; Jie Deng; Yin Ma; Jing Wen; Xiaoqiu Li; Songyu Liu; Yulu Zhang; Jinyan Wan; Nan Li; Rui Ao
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.